|
Posted by : Admin
on Friday, December 14, 2007 - 12:30 PM EST |
 Catalyst Pharmaceutical Partners, Inc., a specialty pharmaceutical company, announced positive results of Phase II study of vigabatrin for the treatment of cocaine addiction. The company's lead compound CPP-109 is bioequivalent to vigabatrin.
The study is determined to study the effectiveness of vigabatrin in treating cocaine addiction. The results showed that a significantly greater number of subjects treated with vigabatrin were able to abstain from cocaine usage during the last three weeks of the dosing period compared to those receiving placebo.
Achievement of abstinence for an extended period during treatment is the critical first step for cocaine addicted patients to potentially achieve abstinence for much longer time periods. The data confirm the positive results seen in two previous open-label trials conducted in 2003 and 2004 by the same investigators.
The company also said that it would evaluate the methodology and results for the patients' potential applicability to its ongoing Phase II trial evaluating CPP-109 for the treatment of cocaine addiction and its Phase II trial evaluating CPP-109 for the treatment of methamphetamine addiction.
Patrick McEnany, Chief Executive Officer of Catalysts said, "This trial represents a key development in the field of cocaine addiction research. CPP-109, our product candidate based on vigabatrin, could have a significant impact on how patients struggling with cocaine addiction will be treated in the future."
Catalyst pharmaceutical company http://www.catalystpharma.com/index.htm
|
Home
Contact Us
Search
Chat Rooms
Forum
Disclaimer & Policies
